Navigation Links
Discovery could lead to anti-clotting drugs with less risk of bleeding
Date:10/28/2013

Researchers at the University of Illinois at Chicago have discovered a molecular switch that causes small, beneficial clots that stop bleeding to enlarge further during wound healing. By blocking this switch in lab mice, the researchers prevented small clots from growing -- a process that can pose a danger in humans -- while preserving their ability to staunch bleeding. Their findings, published online in Nature, open up the possibility for developing potent anti-clotting drugs that don't raise the risk of bleeding.

"Existing anti-clotting drugs significantly reduce the body's ability to form blood clots, so people on these drugs are at risk of serious bleeding," says Xiaoping Du, professor of pharmacology in the UIC College of Medicine and lead author of the paper. "By exploiting this switch we found, we can develop very powerful drugs that prevent the big clots that cause heart attacks and strokes, while preserving the body's ability to form the smaller, primary clots you need to stop bleeding."

Anti-clotting drugs, also known as blood thinners, can help prevent strokes, heart attacks, and deep vein clots. They are also prescribed to reduce the risk of dangerous clots after surgery. But the drugs also increase the risk of bleeding, and must be used with great care.

Du and colleagues investigated a protein called integrin, found in the cell membrane of platelets, the specialized blood cells that form clots to stop bleeding. Signals given off by injured or torn blood vessels activate integrin, which directs the platelets to bind to the injured blood vessel and to other platelets through a linking-protein called fibrinogen. This cross-linking results in a primary clot, good enough to stop the bleeding in most minor cuts.

The UIC researchers discovered that once fibrinogen gets involved, another molecule called G-alpha-13 latches on to integrin and causes the clot to grow much bigger -- to ensure the bleeding is stopped. Normally, the enlar
'/>"/>

Contact: Sharon Parmet
sparmet@uic.edu
312-413-2695
University of Illinois at Chicago
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
2. Washingtons Life Sciences Discovery Fund awards commercialization grants
3. Discovery could help to develop drugs for organ transplant and cancer patients
4. Feelings of immaturity accompany alcohol misuse into adulthood; discovery could improve treatments
5. H1N1 discovery paves way for universal flu vaccine: UBC research
6. Scientists make breakthrough in bile duct cancer with discovery of new gene mutations
7. Researchers make promising discovery in pursuit of effective lymphoma treatments
8. Discovery suggests new combination therapy strategy for basal-like breast cancers
9. Discovery of Gene May Lead to New Male Contraceptive
10. 5 more pharmaceutical companies join NIH initiative to speed therapeutic discovery
11. Illnesses in Colorado childrens hospital prompts discovery of contaminated alcohol pads
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... The New Foundation AZ ... by the end will cost the 501(c) organization nearly $1 million, will both update ... , “We took it down to the studs,” said Geraldine Leary, the New ...
(Date:7/29/2015)... Charlotte, North Carolina (PRWEB) , ... July 29, ... ... that MetLife, Inc ., a global provider of life insurance, annuities, employee ... Adventure Team Challenge North Carolina inclusive sporting event taking place in Charlotte, ...
(Date:7/29/2015)... ... July 29, 2015 , ... Indiana is known for ... also the home of Zerorez Indianapolis, which plans to expand across the state. , ... is our second full year in business and we should double our first year’s ...
(Date:7/29/2015)... San Antonio, TX (PRWEB) , ... July 29, ... ... developed by a board-certified gastroenterologist, has launched a chewable version of its EndoMune ... tablet to be a tasty, all-natural supplement that children can enjoy to maintain ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... which Breckheimer oversees. In her role, Powers is responsible for driving growth and ... announcement, Breckheimer commented, “Gina’s track record as an effective leader within the ITW ...
Breaking Medicine News(10 mins):Health News:The New Foundation AZ Renovates Residential Dorms for Youth in Crisis 2Health News:The New Foundation AZ Renovates Residential Dorms for Youth in Crisis 3Health News:MetLife Joins World T.E.A.M. Sports’ Adventure Team Challenge North Carolina as Presenting Sponsor 2Health News:MetLife Joins World T.E.A.M. Sports’ Adventure Team Challenge North Carolina as Presenting Sponsor 3Health News:Zerorez® Announces Plans to Roll Across Indiana—“The Crossroads of America.” 2Health News:Zerorez® Announces Plans to Roll Across Indiana—“The Crossroads of America.” 3Health News:EndoMune Advanced Probiotic adds Chewable Tablet for Kids to Product Line 2Health News:EndoMune Advanced Probiotic adds Chewable Tablet for Kids to Product Line 3Health News:Gina Powers Named Vice President & General Manager of ITW Dynatec 2Health News:Gina Powers Named Vice President & General Manager of ITW Dynatec 3
... Feb. 26 WoundEducators.com, LLC, an online educational ... wound management, is proud to receive endorsement from ... our online course in wound management. This ... company,s web-based home study wound course, Evidence-Based Wound ...
... and virulent strains, study finds , , THURSDAY, ... two FDA-approved drugs shows promise in treating extensively ... In laboratory tests, researchers at the Albert Einstein ... Allergy and Infectious Diseases found that a combination ...
... a honey of a garden, the judges unanimously agreed. ... interconnected gardens with such names as "Honeycomb Hideout," "Nectar ... garden design competition, a gift to the University of ... design, the work of landscape architects Donald Sibbett and ...
... Engines WASHINGTON, Feb. 26 Environmental Defense Fund ... EPA Administrator Lisa Jackson to protect public health ... operation today . The emission standards would ... hazardous volatile organic compounds, lethal particulate pollution, carbon ...
... 26 Arbor Pharmaceuticals, a specialty,pharmaceutical company focused ... has launched XYLAREX - a first-in-class nonantibiotic,for the ... ear,infections). XYLAREX is a novel oral solution ... of ear infections children experience. The primary,ingredient ...
... Lecture and Podcast VOORHEES, N.J., Feb. 26 ... (CDI) is changing and has been marked by ... Furthermore, the epidemic strain continues to be reported ... United States, and worldwide.To address the need for ...
Cached Medicine News:Health News:Wound Care Certification Course Endorsed by the American College of Certified Wound Specialists 2Health News:Antibiotic Combo Fights Resistant TB 2Health News:Sausalito team wins Häagen-Dazs-UC Davis 'Bee Friendly' garden competition 2Health News:Sausalito team wins Häagen-Dazs-UC Davis 'Bee Friendly' garden competition 3Health News:Environmental Defense Fund Welcomes EPA Clean Air Standards to Reduce Hazardous Diesel Pollution 2Health News:Environmental Defense Fund Welcomes EPA Clean Air Standards to Reduce Hazardous Diesel Pollution 3Health News:Environmental Defense Fund Welcomes EPA Clean Air Standards to Reduce Hazardous Diesel Pollution 4Health News:Arbor Pharmaceuticals Announces the Launch of XYLAREX(TM) - A New Nonantibiotic Product for the Dietary Management of Recurrent Ear Infections in Children 2Health News:Interview with GI Experts: Discussions in Clostridium difficile 2
(Date:7/29/2015)... MARLBOROUGH, Mass. , July 29, 2015  RXi ... focused on discovering and developing innovative therapeutics primarily in ... it will report financial results for the second quarter ... after the close of the U.S. financial markets.  ... 4:30 p.m. EDT. The webcast link is available under ...
(Date:7/29/2015)... July 29, 2015 According to ... Market - Growth, Trends & Forecasts (2015-2020) , published ... be worth US$ 2.85 billion by the end of ... the largest market globally accounting for more than 36% ... Therapeutic Vaccines is expected to grow at a CAGR ...
(Date:7/28/2015)... , July 28, 2015   Heska Corporation ... a provider of  advanced veterinary diagnostic and other ... of the new Element i ® Immunodiagnostic ... screening for key health concerns, including thyroid disorders, ... is a compact bench top analyzer that delivers ...
Breaking Medicine Technology:RXi Pharmaceuticals to Webcast Second Quarter 2015 Financial Results on Wednesday, August 12, 2015 2RXi Pharmaceuticals to Webcast Second Quarter 2015 Financial Results on Wednesday, August 12, 2015 3New Approaches and Technical Advances by Major Players Like Novartis, Merck KGaA, Pfizer, GlaxoSmithKline and Others to Elevate the Global Therapeutic Vaccines Market 2New Approaches and Technical Advances by Major Players Like Novartis, Merck KGaA, Pfizer, GlaxoSmithKline and Others to Elevate the Global Therapeutic Vaccines Market 3Heska Announces Veterinary Market's first and only point of care Analyzer for TSH, Total T4, and Cortisol results in minutes 2Heska Announces Veterinary Market's first and only point of care Analyzer for TSH, Total T4, and Cortisol results in minutes 3
... PALO ALTO, Calif., March 8, 2011 Jazz Pharmaceuticals, Inc. ... will be providing a business update at two upcoming investor ... financial officer, will provide an update at the ROTH 23rd ... Monday, March 14, 2011 at 4:30 p.m. Pacific Time ...
... Warner Chilcott plc (Nasdaq: WCRX ) ... its ordinary shares by certain selling shareholders. The selling ... Morgan Partners (advised by CCMP Capital) and Thomas H. ... management. The offering is being conducted as a public ...
Cached Medicine Technology:Warner Chilcott Announces Secondary Equity Offering 2Warner Chilcott Announces Secondary Equity Offering 3Warner Chilcott Announces Secondary Equity Offering 4
For the quantitative in vitro determination of creatinine in serum, plasma or urine....
The PHOS method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of phosphorus in serum....
The TBIL method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of total bilirubin in serum and plasma...
For the quantitative in vitro determination of total and direct bilirubin in serum or plasma....
Medicine Products: